Melanoma News and Research

Latest Melanoma News and Research

Caffeine combats skin cancer risk

Drinking three or more cups of caffeinated coffee a day can significantly reduce a person’s risk for basal cell carcinoma, show study findings.

10 Jul 2012

Sox10 gene plays a central role in melanoma

Black skin cancer, also known as melanoma, is particularly aggressive and becoming increasingly common in Switzerland. Despite intensive research, however, there is still no treatment. Researchers from the University of Zurich have now discovered a gene that plays a central role in black skin cancer. Suppressing this gene in mice inhibits the development of melanoma and its proliferation - a discovery that could pave the way for new forms of therapy.

10 Jul 2012

Merck, PDS Biotechnology enter licensing agreement for Versamune

PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.

9 Jul 2012

High expression of interleukin-9 in immune cells inhibits melanoma growth

Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.

9 Jul 2012

Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

5 Jul 2012

Neighboring non-cancer cells may contribute to drug resistance

One of cancer's most frightening characteristics is its ability to return after treatment. In the case of many forms of cancer, including the skin cancer known as melanoma, tailored drugs can eradicate cancer cells in the lab, but often produce only partial, temporary responses in patients. One of the burning questions in the field of cancer research has been and remains: how does cancer evade drug treatment?

5 Jul 2012

Cancer Therapeutics reveals proof of concept for second development drug

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.

4 Jul 2012

New method promotes selection and growth of dangerous cancer cells

The news a cancer patient most fears is that the disease has spread and become much more difficult to treat. A new method to isolate and grow the most dangerous cancer cells could enable new research into how cancer spreads and, ultimately, how to fight it.

3 Jul 2012

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.

3 Jul 2012

Caffeinated coffee intake may reduce risk of basal cell carcinoma

Increasing the number of cups of caffeinated coffee you drink could lower your risk of developing the most common form of skin cancer, basal cell carcinoma, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

Second potential immune checkpoint target for cancer immunotherapy announced by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today results demonstrating the therapeutic potential of CGEN-15022, a Compugen-discovered B7/CD28-like membrane protein, as an immune checkpoint target for treatment of multiple cancers.

27 Jun 2012

Indoor tanning beds banned for minors

Rhode Island took a great step today to protect youth from the dangers of skin cancer by prohibiting the use of indoor tanning beds by minors under the age of 18 without parental consent. This important action is based on significant scientific evidence that indoor tanning is undeniably linked to increased risk of developing melanoma and other forms of skin cancer.

27 Jun 2012

Top-line final data from Provectus’ PV-10 phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that top-line final data from its phase 2 clinical trial of PV-10 for metastatic melanoma were presented at the 2nd European Post-Chicago Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

27 Jun 2012

Having antibodies for cutaneous HPV and sun exposure can act synergistically in BCC, SCC

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and the German Cancer Research Center in Heidelberg have found that having antibodies for cutaneous types of human papillomavirus (HPV), coupled with sun exposure (ultraviolet radiation) or poor tanning ability, can act "synergistically" in the development of non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

26 Jun 2012

New drug better than chemotherapy for skin cancer patients

A new drug, dabrafenib, shows improvements over chemotherapy for patients suffering from a form of advanced skin cancer, according to the results of a Phase III study (“BREAK-3” trial) published Online First in the Lancet.

26 Jun 2012

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

Skin patch treatment kills common skin cancer

A skin patch treatment for a common type of skin cancer called basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.

22 Jun 2012

A potential drug target for NK/T-cell lymphoma

A discovery by Van Andel Institute researchers has identified a potential drug target for NK/T-cell lymphoma, a type of cancer responsible for claiming the life of a close friend and fellow researcher.

22 Jun 2012

Grb2 switch controls normal signaling through fibroblast growth factor receptor

Once considered merely a passive link between proteins that matter, Grb2 - pronounced "grab2" - actually lives up to its nickname with its controlling grip on an important cell signaling pathway, scientists at The University of Texas MD Anderson Cancer Center report in the June 22 issue of Cell.

22 Jun 2012